Should You Buy Gilead Sciences in April?

Should You Buy Gilead Sciences in April?
Jim Halley, The Motley Fool
·4 min read

Last year, Gilead Sciences (NASDAQ: GILD) showed that one drug can make a huge difference in a company's bottom line. Veklury, better known as remdesivir, earned emergency use authorization (EUA) and then full authorization from the U.S. Food and Drug Administration (FDA), and become the first treatment for COVID-19. It might have been even more had the World Health Organization (WHO) not recommended against its use last November.